Safety and Efficacy of a Standardized Extract from Leaves of *Dalbergia Sissoo* in Healing of Long Bone Fracture: A Pilot Clinical Study

Dixit Pankaj¹, Pande Shishir¹ and Deshmukh Amol²*

¹Ayurved Seva Sangh Ayurved College and Hospital, India
²Pharmanza Herbal Pvt.Ltd, India

Introduction: Healing of long bone fracture is a complex phenomenon and usually take months to years to recover completely. Varied products from different systems of medicine have been tried to accelerate fracture healing process. In recent preclinical studies it is found that standardized extract of leaves of *Dalbergia sissoo* accelerated fracture healing in rats by stimulating bone regeneration. The bone regeneration activity of herb is attributed to a novel compound CAFG.

Aim: To evaluate the safety and efficacy of a standardized extract of *Dalbergia sissoo* (DSE) leaves in patients with long bone fracture.

Materials and Methods: This was a single arm, pilot clinical study conducted at Nashik, Maharashtra. A total of 16 patients with lower or upper limbs long bone fracture were enrolled in this study to receive oral 300mg DSE capsules (twice daily for 2 months). The primary endpoint was fracture healing, assessed radiologically at week 2, 4, 6 and 8. Safety was evaluated by monitoring adverse event and biochemical investigations.

Results: Treatment with DSE resulted in fading of fracture line in subsequent follow up visits and restored functional mobility. At the end of the study (week 8) all fractures were healed. No clinically significant adverse events were reported. At the end of the study, SGOT, SGPT and urea were significantly reduced compared with baseline.

Conclusion: Overall, this study demonstrated that a standardized extract of DSE leaves was well tolerated with no safety concern and has a potential of fracture healing.

Keywords: *Dalbergia sissoo* extract; CAFG; Fracture healing

Abbreviations: DSE: *Dalbergia Sissoo* Extract; SGOT: Serum Glutamic Oxaloacetic Transaminase; SGPT: Serum Glutamic Pyruvic Transaminase

Introduction

Fracture healing is a complex cascade that involves many local and systemic regulatory factors, cytokines and hormones that recapitulates the sequential stages of embryonic endochondral ossification [1]. A few hours after the occurrence of fracture, the extra vascular blood cells clot and form a hematoma. This fracture hematoma is enriched with several signalling molecules including interleukin(IL)-1, IL-6, tumor necrosis factor-α (TNF-α), transforming growth factor β (TGFβ), fibroblast growth factors (FGF), insulin-like growth factor (IGF), platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF). These factors regulate subsequent recruitment of endothelial cells, platelets, macrophages, monocytes and multi potent mesenchymal stem cells at fracture site and induce a cascade of cellular events to recruit osteoblast and osteoclast [2,3]. These loose aggregate of cells with several growth factors, interspersed with small blood vessels is known as granulation tissue. The phase of granulation tissue formation is termed as reactive phase. This reactive phase precedes the reparative phase of healing which involves cartilaginous soft callus formation. Subsequently, the cartilaginous callus is resorbed and gradually replaced with woven bone, which is ultimately mineralized and undergo remodelling event to restore the original cortex of the lamellar bone [4].

Although there are quite a few clinical agents to manage bone pathology there is no orally active pharmacological agent for rapid fracture healing. As a result, traditional remedies are
being re-evaluated through reverse pharmacology to validate the
efficacy and discover novel pharmacological agent for clinical
interventions [5].

An ayurvedic herb Cissus quadrangularis (CQ) is used
traditionally for accelerating process of fracture healing. There
are few clinical studies reporting the role of CQ in fracture
healing, the compound(s) responsible for such effect remains
unknown [6-10]. Recent preclinical studies have shown that
a standardized extract made from leaves of Dalbergia sissoo
(DSE) has significant osteogenic effect which was attributed to
a novel compound caviunin 7-O-[β-D-apiofuranosyl-(1→6)-β-D-
glucopyranoside(CAFG) [11,12]. In rodents, CAFG accelerated
fracture healing by stimulating bone regeneration at the fracture
site with 1- and 5mg/kg oral dose [12].

Hence, this pilot clinical study was designed to assess the
safety of DSE in patients with long bone fracture. In addition,
efficacy of DSE was also assessed to support further development
of this drug for potential use in this population.

Materials and Methods

Study design

This was a prospective, interventional, single-centre, single
arm, pilot clinical study conducted at Nashik, Maharashtra
(Clinical trial registration no. CTRI/2015/06/005850). Patients
with long bone fracture(s) of upper or lower arm visiting Shalya
Tantra outpatient department of Ayurved Seva Sanga Hospital,
Nashik, were screened and enrolled if fulfilled eligibility criteria.
Enrolled patients were provided with study medication (2
capsules of DSE, twice a day for 2 months). Study visits were
planned on Day 15,30,45 and 60. At each study visit, clinical and
radiological examinations were conducted to evaluate the safety
and improvement in fracture healing. Biochemical investigations
were done at baseline and at the end of study.

Study participants

Patients of either sex between 18 and 60 years of age with
long bone fracture(s) of upper or lower arm (confirmed by
radiological report) were enrolled in the study within 5 days
from the day of fracture. Patients with pathological fractures,
diabetes, end organ failure or pregnant women excluded from
the study.

The study was conducted in accordance with the principles
that have their origin in the Declaration of Helsinki (2013)
and that are consistent with International Conference on
Harmonization (ICH) guidelines on Good Clinical Practices (GCP)
and applicable regulatory requirements. The study protocol was
reviewed and approved by the Institutional Ethics Committee.
Written informed consent was obtained from each patient for
participation in this study.

Study medication

Capsules containing 300mg of alcoholic extract of DSE
leaves were supplied by Pharmanza Herbal Pvt. Ltd. The
extract is based on a patent (EP 2705047 B1) which owned by
Council of Scientific and Industrial Research, New Delhi, India.
DSE contained Caviunin-70-[β-D-apiofuranosyl-(1→6)-β-D-
glucopyranoside(CAFG) 0.67%, Biochanin-7-O-glucoside 1.5%,
Genstein 0.75%, Pratensein 0.2% and Biochanin-A, 1%.

Assessments

Assessment included fracture healing (clinical and
radiological). Clinical assessment included fracture site pain
and functionality (ability to walk or perform daily activities).
Pain was assessed using visual analogue scale (VAS) having
score from 0 to 10 (lesser the score greater the improvement)
and functionality (patient’s ability to walk or perform daily
activity) was graded from 0 to 3 (greater score shows greater
improvement). Radiological criteria included fading of fracture
line in x-rays of subsequent follow-up visits. Safety was assessed
throughout the study duration. At baseline and at the end
of study, levels of serum glutamic oxalo acetic transaminase
(SGOT) and serum glutamic pyruvic transaminase (SGPT) were
also recorded to assess hepatotoxicity, and blood urea nitrogen
(BUN) and serum creatinine levels to assess renal toxicity. Serum
biochemical parameters were measured by Automated-analyzer
(Sysmex) using kinetic assay method [13-15].

Statistical Analysis

Baseline scores of clinical biochemical parameters of all
patients were compared with the scores of their clinical and
biochemical parameters on study Day 15,30,45 and 60. Effect
of treatment was analyzed by using paired student’s t test with
significance level of 0.01.

Results

Total twenty patients with long bone fractures were enrolled
in the study and of which 16 patients completed the study. Four
patients withdrew consent and excluded from the analysis.
The mean age of patients who completed the study was 39.6
years which ranged from30 to 52 years. The fracture sites were
humerus, ulna, fibula (25%; n=4, each) and radius and tibia
(12.5%; n=2, each). At baseline, the mean (SD) VAS score for
fracture pain was 9.1(0.6) which reduced significantly (p<0.01)
to 1.1(1.2) by end of the study. Baseline VAS score for pain
experienced by patient at the time of examination (palpation)
of fracture site was 9.6(0.7) which reduced significantly (p<0.01)
to 0.9(1.2) in 8 weeks. Patient’s ability to walk or perform daily
activities improved significantly (p<0.01) from baseline 0(0) to
2.1(0.8) by end of the study (Table1).

Radiological assessment

Radiological assessment which was performed to confirm
clinical fracture healing showed fading of fracture line in
subsequent study visits. Fracture line which was visible at the
baseline faded in subsequent study visits (Figure 1 & 2).
Biochemical parameters

The mean (SD) SGOT, SGPT and urea at the baseline were 32.3(15) IU, 31.6(13.6) IU, and 30.9(5.4)mg%, respectively, which reduced significantly (P<0.01) at the end of study visit to 24.9(9.7) IU, 25(9.3) IU and 27.3(2.9)mg%. The level of creatinine at baseline was 1.0(0.2)mg%, which was 1.0(0.2)mg% in the end of study (P>0.01) (Table 1).

Table 1: Level of clinical and haematological parameters at baseline and at follow up visits.

<table>
<thead>
<tr>
<th>Clinical Parameters</th>
<th>Base Line</th>
<th>1st Visit (2nd Week)</th>
<th>2nd Visit (4th Week)</th>
<th>3rd Visit (6th Week)</th>
<th>4th Visit (8th Week)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain</td>
<td>Mean(SD)</td>
<td>9.125(0.62)</td>
<td>6.875(1.83)</td>
<td>4.875(1.97)</td>
<td>3(2.07)</td>
</tr>
<tr>
<td></td>
<td>t score</td>
<td>6.267</td>
<td>9.711</td>
<td>12.922</td>
<td>25.237</td>
</tr>
<tr>
<td></td>
<td>p</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td></td>
<td>significance</td>
<td>significant</td>
<td>significant</td>
<td>significant</td>
<td>significant</td>
</tr>
<tr>
<td>Pain/Tenderness While Examining Fracture Area</td>
<td>Mean(SD)</td>
<td>9.625(0.72)</td>
<td>6.625(2.63)</td>
<td>4.75(2.87)</td>
<td>2.625(2.19)</td>
</tr>
<tr>
<td></td>
<td>t score</td>
<td>5.068</td>
<td>7.076</td>
<td>13.54</td>
<td>26.042</td>
</tr>
<tr>
<td></td>
<td>p</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td></td>
<td>significance</td>
<td>significant</td>
<td>significant</td>
<td>significant</td>
<td>significant</td>
</tr>
</tbody>
</table>
### Discussion

To authors knowledge this was the first study to assess fracture healing properties of DSE in humans. Results from this pilot study demonstrated that administration of DSE in patients with long bone fracture was generally tolerable with no safety concerns. At the end of the study all patients were comfortable in doing their daily routine activities with minimal pain or discomfort. After treatment with study medication these patients showed significant improvement in all clinical parameters consistently throughout the study visits. Radiological assessment revealed the fading of fracture line which confirmed the clinical healing of the fractures. The average healing time for such long bone fracture is said to be between 12-16 weeks [16,17] which was reduced approximately by 30-40% with the use of DSE.

These results support the similar observations noted during the preclinical studies, where DSE showed increased bone regeneration at the fracture site of rat long bone. The CAFG, an osteogenic compound present in DSE, promoted bone regeneration at the site of fracture in long bones of ovar-intact and ovariectomized mice [12].

In a fracture healing study when 10 interlocked nail fixed fracture patients treated with the poly-herbal formulation containing CQ (UNIBONE capsules) the fractures were found to have healed in 12-14 weeks. The average fracture healing time for those patients was said to be 16-20 weeks, which was decrease by 25-30% with the use of UNIBONE [6]. When the fracture healing efficacy was compared in adult rats between CQ and DSE given per oral, the later was found to be more effective (unpublished data, personal communication with Dr.Naibedya Chattopadhyay, CSIR-Central Drug Research Institute, Lucknow, India).

Overall, administration of DSE in patients with long bone fracture was well-tolerated with no safety signals. There were no deaths, serious adverse events, or discontinuations due to adverse events during the study. One female patient reported stomach upset which was relieved without any medication before study completion. The baseline levels of SGOT, SGPT and urea were reduced significantly by the end of the study. Though the reduction in the level of creatinine was not significant (p>0.05), the values of creatinine were in normal limits. This indicates safety of DSE when taken in the doses of 1200mg/day for the period of 2 months.

Authors acknowledge following limitations of this study. The study was limited with 1) small sample size, 2) fractures of different sites, 3) no comparator (active or placebo). Authors also acknowledge that it could be difficult to explain if the fracture healing was due to natural process or due to DSE, however based on previous data we hypothesize that DSE has the potential to accelerate the healing of fracture. Further studies with larger sample size and using fracture healing biomarkers, more detailed radiological and biochemical investigations are warranted to confirm these results.
Conclusion

Though the study was limited by small sample size with no direct comparator, it provides insights on the safety and efficacy of DSE in the patients with long bone fracture. Long term study with larger size using fracture healing biomarkers is warranted to confirm these results.

Acknowledgement

Authors would like to thank Pharmanza Herbal Pvt. Ltd. for providing study medication and fund for the study.

References


This work is licensed under Creative Commons Attribution 4.0 License
DOI: 10.19080/JCMAH.2018.04.555654


Your next submission with Juniper Publishers will reach you the below assets
- Quality Editorial service
- Swift Peer Review
- Reprints availability
- E-prints Service
- Manuscript Podcast for convenient understanding
- Global attainment for your research
- Manuscript accessibility in different formats
  - (Pdf, E-pub, Full Text, Audio)
- Unceasing customer service

Track the below URL for one-step submission
https://juniperpublishers.com/online-submission.php